LIQUID BIOPSY-GUIDED THERAPY SWITCHING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Market Segmentation

• Biomarker Type Insights (Revenue, USD Bn, 2021 - 2033)

  • ESR1 Mutations
  • EGFR Mutations
  • KRAS Mutations
  • Other Actionable Biomarkers

• Liquid Biopsy Technology Insights (Revenue, USD Bn, 2021 - 2033)

  • Next-Generation Sequencing (NGS)
  • Digital PCR (dPCR/ddPCR)
  • PCR-Based Assays

• Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Others

• Therapy Switching Approach Insights (Revenue, USD Bn, 2021 - 2033)

  • Switching Treatment Before Clinical Progression Based on Molecular Resistance
  • Switching Treatment at Clinical or Radiographic Progression
  • Switching Treatment Based on Molecular Response or Emerging Biomarkers

• End User Insights (Revenue, USD Bn, 2021 - 2033)

  • Hospitals and Oncology Centers
  • Diagnostic and Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Others

• Regional Insights (Revenue, USD Bn, 2021 - 2033)

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa